Skip to Main Content

Paper Details

Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme.
1
2023
ASCVD, Janus kinase, MACE, Patients, Tofacitinib, UC, Ulcerative Colitis, atherosclerotic cardiovascular [CV] disease, inflammatory bowel disease, patient, patients, tofacitinib, ulcerative colitis
Author NameAffiliation
Stefan SchreiberUniversity Hospital Schleswig-Holstein, Kiel University
  • 1 - 1

Datasets

Release 1.2